Tonix Pharmaceuticals
TNXP · Nasdaq · United States
Share price · TNXP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TNXP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026-16.3%
Nothing announced by TNXP that day or the session before.
- 10 Nov 2026-8.7%
- 9 Nov 2026-5.3%
- 19 Oct 2026-5.1%
- 12 Oct 2026-9.0%
Nothing announced by TNXP that day or the session before.
- 5 Oct 2026-9.4%
- 20 Jul 2026-11.7%
Nothing announced by TNXP that day or the session before.
- 15 May 2026+11.7%
- 26 Mar 2026-8.3%
- 19 Mar 2026+11.1%
Share of unusual movement by asset
For each asset, the share of TNXP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
cyclobenzaprine(Tonmya) | Approved | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)Small molecule | Major Depressive DisorderFibromyalgia |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Phase 2 | Cocaine (enzymatic hydrolysis)Protein / enzyme therapeutic | Cocaine Intoxication | |
| Phase 2 | CD40 ligand (CD40L / CD154)Monoclonal antibody | Kidney Transplant Rejection |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
February 2028 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $17M | $26M | $163M | $53M-$41M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $14M | $19M | $177M | $41M-$42M operating cash flow | report ↗ |
| 2026-Q1 | $6.9M | $18M | $186M | $40M-$42M operating cash flow | report ↗ |
| 2025-Q3 | $3.3M | $9.3M | $191M | $32M-$29M operating cash flow | report ↗ |
| 2025-Q2 | $2.0M | $11M | $126M | $28M-$15M operating cash flow | report ↗ |
| 2025-Q1 | $2.4M | $7.4M | $133M | $17M-$17M operating cash flow | report ↗ |
| 2024-Q3 | $2.8M | $9.1M | $29M | $14M-$19M operating cash flow | report ↗ |
| 2024-Q2 | $2.2M | $9.7M | $5.1M | $79M-$9.9M operating cash flow | report ↗ |
| 2024-Q1 | $2.5M | $13M | $8.0M | $15M-$18M operating cash flow | report ↗ |
| 2023-Q3 | $4.0M | $21M | $7.9M | $28M-$23M operating cash flow | report ↗ |
| 2023-Q2 | — | $22M | $26M | $28M-$23M operating cash flow | report ↗ |
| 2023-Q1 | — | $27M | $72M | $33M-$33M operating cash flow | report ↗ |
| 2022-Q3 | — | $22M | $140M | $29M-$24M operating cash flow | report ↗ |
| 2022-Q2 | — | $17M | $177M | $23M-$21M operating cash flow | report ↗ |
| 2022-Q1 | — | $18M | $141M | $26M-$31M operating cash flow | report ↗ |
| 2021-Q3 | — | $13M | $183M | $19M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $13M | $44M | $210M | $31M-$100M operating cash flow | report ↗ |
Tonix Pharmaceuticals reported full-year 2025 revenue of $13.11M, up 29.9% YoY, driven largely by the TONMYA launch and existing migraine products. R&D spend was $44.49M, up 11.3% YoY, and cash and equivalents totaled approximately $207.6 million at year-end. The company recorded a net loss of $124.02M for the year.
The company expects its cash resources to fund planned operating and capital expenditure requirements into the first quarter of 2027. TONMYA was FDA-approved in August 2025 and launched on November 17, 2025, with more than 1,500 prescribers, approximately 2,500 patients initiated, and about 4,200 cumulative prescriptions through February 27, 2026. Tonix plans to initiate a U.S. field study in 2027 for TNX-4800 for seasonal prevention of Lyme disease, expects mid-2026 enrollment for the Phase 2 HORIZON study of TNX-102 SL in major depressive disorder, and completed a $20.0 million registered direct offering with Point72 in December 2025.
Insider transactions
Open-market activity, trailing 12 months: 8 purchases ($479K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-11 | LEDERMAN SETH · director, Chief Executive Officer | Open-market purchase | 5,000 | $4.05 | $20K | Form 4 |
| 2026-08-27 | LEDERMAN SETH · director, Chief Executive Officer | Open-market purchase | 2,000 | $13.79 | $28K | Form 4 |
| 2026-08-20 | BAGGER RICHARD H · director | Open-market purchase | 1,000 | $12.60 | $13K | Form 4 |
| 2026-06-30 | SAENGER BRADLEY · Chief Financial Officer | Other (see filing) | 1,453 | $10.91 | $16K | Form 4 |
| 2026-06-12 | Taylor Carolyn E. · director | Open-market purchase | 1,415 | $10.55 | $15K | Form 4 |
| 2026-06-09 | LEDERMAN SETH · director, Chief Executive Officer | Open-market purchase | 5,000 | $11.79 | $59K | Form 4 |
| 2026-06-08 | Stillwell Richard Newcomb · director | Open-market purchase | 5,000 | $11.65 | $58K | Form 4 |
| 2026-05-12 | Taylor Carolyn E. · director | Award / grant (derivative) | 22,700 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 81 reporting institutions held 4.9M shares ($66.8M, 25.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 968,177 | $13.3M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 518,650 | $7.1M |
| 3 | CITADEL ADVISORS LLC | 468,712 | $6.4M |
| 4 | Jones Hill Capital LP | 452,116 | $6.2M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 313,291 | $4.3M |
| 6 | Balyasny Asset Management L.P. | 313,082 | $4.3M |
| 7 | UBS Group AG | 231,678 | $3.2M |
| 8 | STATE STREET CORP | 230,607 | $3.2M |
| 9 | MILLENNIUM MANAGEMENT LLC | 219,673 | $3.0M |
| 10 | AQR CAPITAL MANAGEMENT LLC | 161,208 | $2.2M |
| 11 | Point72 Asset Management, L.P. | 125,414 | $1.7M |
| 12 | NORTHERN TRUST CORP | 100,134 | $1.4M |
| 13 | Nuveen, LLC | 94,561 | $1.3M |
| 14 | VANGUARD FIDUCIARY TRUST CO | 84,270 | $1.2M |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 78,627 | $1.1M |